特发性肺纤维化的分子生物标记物研究进展
Advances in Molecular Biomarkers of Idiopathic Pulmonary Fibrosis
DOI: 10.12677/ACM.2022.121004, PDF,   
作者: 朱 祥：上海交通大学医学院苏州九龙医院呼吸与危重症医学科，江苏 苏州
关键词: 肺纤维化；特发性；生物标记物；进展；Pulmonary Fibrosis； Idiopathic； Biomarkers； Progress
摘要: 特发性肺纤维化(Idiopathic pulmonary fibrosis, IPF)是一种病因不明的间质性肺炎，其中位生存期2~4年。早期IPF一般是无症状的，常常导致诊断及治疗延迟。到目前为止，还没有很好的临床生物标记物可以准确地对IPF进行诊断、评估病情及预后。但是随着IPF研究的不断深入及大量样本的佐证，它们有可能成为有助于诊断、监测疾病进展和治疗效果的有用工具。本文对IPF相关的新的临床生物标志物进行综述，为提高临床诊治提供一定参考。
Abstract: Idiopathic pulmonary fibrosis (IPF) is an interstitial pneumonia of unknown etiology, with a median survival of 2~4 years. Early IPF is usually asymptomatic and often results in delayed diagnosis and treatment. So far, there is no good clinical biomarker that can accurately diagnose, evaluate the condition and prognosis of IPF. However, with further research on IPF and the support of large numbers of samples, they may become useful tools for diagnosis, monitoring of disease progression and treatment effectiveness. In this paper, new clinical biomarkers related to IPF were reviewed to provide some reference for improving clinical diagnosis and treatment.
文章引用：朱祥. 特发性肺纤维化的分子生物标记物研究进展[J]. 临床医学进展, 2022, 12(1): 19-24. https://doi.org/10.12677/ACM.2022.121004

参考文献

[1] Wells, A.U. (2020) Pamrevlumab in Idiopathic Pulmonary Fibrosis. The Lancet Respiratory Medicine, 8, 2-3. [Google Scholar] [CrossRef] 
[2] Duchemann, B., Annesi-Maesano, I., De Naurois, C.J., Sanyal, S., Brillet, P.Y., Brauner, M., et al. (2017) Prevalence and Incidence of Interstitial Lung Diseases in a Multi-Ethnic County of Greater Paris. European Respiratory Journal, 50, Article ID: 1602419. [Google Scholar] [CrossRef] [PubMed]
[3] Esposito, D.B., Lanes, S., Donneyong, M., Holick, C.N., Lasky, J.A., Lederer, D., et al. (2015) Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation. American Journal of Respiratory and Critical Care Medicine, 192, 1200-1207. [Google Scholar] [CrossRef] 
[4] Raghu, G., Remy-Jardin, M., Myers, J.L., Richeldi, L., Ryerson, C.J., Lederer, D.J., et al. (2018) Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 198, e44-e68. [Google Scholar] [CrossRef] 
[5] Buendía-Roldán, I., Mejía, M., Navarro, C. and Selman, M. (2017) Idiopathic Pulmonary Fibrosis: Clinical Behavior and Aging Associated Comorbidities. Respiratory Medicine, 129, 46-52. [Google Scholar] [CrossRef] [PubMed]
[6] 叶俏, 代华平. 特发性肺纤维化诊断和治疗中国专家共识[J]. 中华结核和呼吸杂志, 2016, 39(6): 427-432.
[7] Hadjicharalambous, M.R. and Lindsay, M.A. (2020) Idiopathic Pulmonary Fibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs. International Journal of Molecular Sciences, 21, Article No. 524. [Google Scholar] [CrossRef] [PubMed]
[8] Inoue, Y., Kaner, R.J. and Guiotetal, J. (2020) Diagnosticand Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype. Chest, 158, 646-659. [Google Scholar] [CrossRef] [PubMed]
[9] 姚灵, 李南方, 姚晓光, 等. 肺泡表面活性物质相关蛋白A的研究进展[J]. 医学研究杂志, 2019, 48(12): 24-27.
[10] Chambers, J.E. and Marciniak, S.J. (2014) Cellular Mechanisms of Endoplasmic Reticulum Stress Signaling in Health and Disease. 2. Protein Misfolding and ER Stress. American Journal of Physiology-Cell Physiology, 307, C657-C670. [Google Scholar] [CrossRef] [PubMed]
[11] Liu, L., Qin, J.L., Guo, T., Chen, P., Ouyang, R., Peng, H., et al. (2020) Identification and Functional Characterization of a Novel Surfactant Protein A2 Mutation (p.N207Y) in a Chinese Family with Idiopathic Pulmonary Fibrosis. Molecular Genetics & Genomic Medicine, 8, Article No. e1393. [Google Scholar] [CrossRef] [PubMed]
[12] Seibold, M.A., Wise, A.L., Speer, M.C., Steele, M.P., Brown, K.K., Loyd, J.E., et al. (2011) A Common MUC5B Promoter Polymorphism and Pulmonary Fibrosis. New England Journal of Medicine, 364, 1503-1512. [Google Scholar] [CrossRef] 
[13] Noth, I., Zhang, Y., Ma, S.F., et al. (2013) Genetic Variants Associated with Idiopathic Pulmonary Fibrosis Susceptibility and Mortality: A Genome-Wide Association Study. The Lancet Respiratory Medicine, 1, 309-317. [Google Scholar] [CrossRef] 
[14] Peljto, A.L., Selman, M., Kim, D.S., Murphy, E., Tucker, L., Pardo, A., et al. (2015) The MUC5B Promoter Polymorphism Is Associated with Idiopathic Pulmonary Fibrosis in a Mexican Cohort But Is Rare among Asian Ancestries. Chest, 147, 460-464. [Google Scholar] [CrossRef] [PubMed]
[15] Wang, C., Zhuang, Y., Guo, W., Cao, L., Zhang, H., Xu, L., et al. (2014) Mucin 5B Promoter Polymorphism Is Associated with Susceptibility to Interstitial Lung Diseases in Chinese Males. PLoS ONE, 9, Article ID: e104919. [Google Scholar] [CrossRef] [PubMed]
[16] 宋永娜, 王林纳, 翟建霞, 等. MUC5B启动子rs35705950、rs868903基因多态性与特发性肺纤维化的相关性研究[J]. 临床肺科杂志, 2021, 26(5): 682-686.
[17] Kolb, M., White, E.S. and Gauldie, J. (2016) Mucking around in the Genome: MUC5B in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 193, 355-357. [Google Scholar] [CrossRef] 
[18] Nakano, Y., Yang, I.V., Walts, A.D., Watson, A.M., Helling, B.A., Fletcher, A.A., et al. (2016) MUC5B Promoter Variant rs35705950 Affects MUC5B Expression in the Distal Airways in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 193, 464-466. [Google Scholar] [CrossRef] 
[19] Yamasaki, S., Ishikawa, E., Sakuma, M., Hara, H., Ogata, K. and Saito, T. (2008) Mincle Is an ITAM-Coupled Activating Receptor That Senses Damaged Cells. Nature Immunology, 9, 1179-1188. [Google Scholar] [CrossRef] [PubMed]
[20] Das, B.K., Xia, L., Palandjian, L., Gozani, O., Chyung, Y. and Reed, R. (1999) Characterization of a Protein Complex Containing Spliceosomal Proteins SAPs 49, 130, 145, and 155. Molecular and Cellular Biology, 19, 6796-6802. [Google Scholar] [CrossRef] 
[21] Caspary, F., Shevchenko, A., Wilm, M. and Séraphin, B. (1999) Partial Purification of the Yeast U2 snRNP Reveals a Novel Yeast Pre-mRNA Splicing Factor Required for Pre-Spliceosome Assembly. EMBO J, 18, 3463-3474. [Google Scholar] [CrossRef] [PubMed]
[22] Martinez, E., Palhan, V.B., Tjernberg, A., Lymar, E.S., Gamper, A.M., Kundu, T.K., et al. (2001) Human STAGA Complex Is a Chromatin-Acetylating Transcription Coactivator That Interacts with Pre-mRNA Splicing and DNA Damage-Binding Factors in Vivo. Molecular and Cellular Biology, 21, 6782-6795. [Google Scholar] [CrossRef] 
[23] Chiffoleau, E. (2018) C-Type Lectin-Like Receptors as Emerging Orchestrators of Sterile Inflammation Represent Potential Therapeutic Targets. Frontiers in Immunology, 9, Article No. 227. [Google Scholar] [CrossRef] [PubMed]
[24] Gong, W., Guo, K., Zheng, T., Fang, M., Xie, H., Li, W., et al. (2020) Preliminary Exploration of the Potential of Spliceosome-Associated Protein 130 for Predicting Disease Severity in Crohn’s Disease. Annals of the New York Academy of Sciences, 1462, 128-138. [Google Scholar] [CrossRef] [PubMed]
[25] Liu, K., Liu, D., Feng, Y., Zhang, H., Zeng, D., Liu, Q., et al. (2020) Spliceosome-Associated Protein 130: A Novel Biomarker for Idiopathic Pulmonary Fibrosis. Annals of Translational Medicine, 8, Article No. 986. [Google Scholar] [CrossRef] [PubMed]
[26] Martínez, V.G., Moestrup, S.K., Holmskov, U., Mollenhauer, J. and Lozano, F. (2011) The Conserved Scavenger Receptor Cysteine-Rich Super Family in Therapy and Diagnosis. Pharmacological Reviews, 63, 967-1000. [Google Scholar] [CrossRef] [PubMed]
[27] Gordon, S. and Martinez, F.O. (2010) Alternative Activation of Macrophages: Mechanism and Functions. Immunity, 32, 593-604. [Google Scholar] [CrossRef] [PubMed]
[28] Fabriek, B.O., Dijkstra, C.D. and van den Berg, T.K. (2005) The Macrophage Scavenger Receptor CD163. Immunobiology, 210, 153-160. [Google Scholar] [CrossRef] [PubMed]
[29] Guo, L., Akahori, H., Harari, E., Smith, S.L., Polavarapu, R., Karmali, V., et al. (2018) CD163+ Macrophages Promote Angiogenesis and Vascular Permeability Accompanied by Inflammation in Atherosclerosis. Journal of Clinical Investigation, 128, 1106-1124. [Google Scholar] [CrossRef] 
[30] Weaver, L.K., Hintz-Goldstein, K.A., Pioli, P.A., Wardwell, K., Qureshi, N., Vogel, S.N., et al. (2006) Pivotal Advance: Activation of Cell Surface Toll-Like Receptors Causes Shedding of the Hemoglobin Scavenger Receptor CD163. Journal of Leukocyte Biology, 80, 26-35. [Google Scholar] [CrossRef] [PubMed]
[31] Hassan, W.A., Baraka, E.A., Elnady, B.M., Gouda, T.M. amd Fouad, N. (2016) Serum Soluble CD163 and Its Association with Various Disease Parameters in Patients with Systemic Sclerosis. European Journal of Rheumatology, 3, 95-100. [Google Scholar] [CrossRef] [PubMed]
[32] Zhang, Y., Huang, C., Nie, Y., Liu, Q., Xiao, N., Liu, L., et al. (2021) Soluble CD163 Is a Predictor of Mortality in Patients with Decompensated Cirrhosis. Frontiers in Medicine, 8, Article ID: 698502. [Google Scholar] [CrossRef] [PubMed]
[33] Scott, M.K.D., Quinn, K., Li, Q., Carroll, R., Warsinske, H., Vallania, F., et al. (2019) Increased Monocyte Count as a Cellular Biomarker for Poor Outcomes in Fibrotic Diseases: A Retrospective, Multicentre Cohort Study. Lancet Respiratory Medicine, 7, 497-508. [Google Scholar] [CrossRef] 
[34] Yamashita, M., Saito, R., Yasuhira, S., Fukuda, Y., Sasamo, H., Sugai, T., et al. (2018) Distinct Profiles of CD163-Positive Macrophages in Idiopathic Interstitial Pneumonias. Journal of Immunology Research, 2018, Article ID: 1436236. [Google Scholar] [CrossRef] [PubMed]
[35] Yamashita, M., Utsumi, Y., Nagashima, H., Nitanai, H. and Yamauchi, K. (2021) S100A9/CD163 Expression Profiles in Classical Monocytes as Biomarkers to Discriminate Idiopathic Pulmonary Fibrosis from Idiopathic Nonspecific Interstitial Pneumonia. Scientific Reports, 11, Article No. 121 35. [Google Scholar] [CrossRef] [PubMed]
[36] Ye, Q., Dalavanga, Y., Poulakis, N., Sixt, S.U., Guzman, J. and Costabel, U. (2008) Decreased Expression of Haem Oxygenase-1 by Alveolar Macrophages in Idiopathic Pulmonary Fibrosis. European Respiratory Journal, 31, 1030-1036. [Google Scholar] [CrossRef] [PubMed]
[37] Ishikawa, N., Hattori, N., Yokoyama, A. and Kohno, N. (2012) Utility of KL-6/MUC1 in the Clinical Management of Interstitial Lung Diseases. Respiratory Investigation, 50, 3-13. [Google Scholar] [CrossRef] [PubMed]
[38] Xue, M., Guo, Z., Zhou, L., et al. (2020) Evaluation of the Diagnostic Efficacies of Serological Markers Kl-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia A67. Structure-Function Relationship, 98, 534-545.
[39] Guo, L., Yang, Y., Liu, F., Jiang, C., Yang, Y., Pu, H., et al. (2020) Clinical Research on Prognostic Evaluation of Subjects with IPF by Peripheral Blood Biomarkers, Quantitative Imaging Characteristics and Pulmonary Function Parameters. Archivos de Bronconeumología, 56, 365-372. [Google Scholar] [CrossRef] [PubMed]
[40] Ohshimo, S., Ishikawa, N., Horimasu, Y., Hattori, N., Hirohashi, N., Tanigawa, K., et al. (2014) Baseline KL-6 Predicts Increased Risk for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Respiratory Medicine, 108, 1031-1039. [Google Scholar] [CrossRef] [PubMed]
[41] Aloisio, E., Braga, F., Puricelli, C. and Panteghini, M. (2021) Prognostic Role of Krebs von den Lungen-6 (KL-6) Measurement in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Clinical Chemistry and Laboratory Medicine d, 59, 1400-1408. [Google Scholar] [CrossRef] [PubMed]
[42] Zhu, C., Zhao, Y.B., Kong, L.F., Li, Z.H. and Kang, J. (2016) The Expression and Clinical Role of KL-6 in Serum and BALF of Patients with Different Diffuse Interstitial Lung Diseases. Chin. Chinese Journal of Tuberculosis and Respiratory Diseases, 39, 93-97.
[43] Bennett, D., Salvini, M., Fui, A., Cillis, G., Cameli, P., Mazzei, M.A., et al. (2019) Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP. Inflammation, 42, 463-470. [Google Scholar] [CrossRef] [PubMed]
[44] Bonella, F., Ohshimo, S., Boerner, E., et al. (2015) Serum Kl-6 Levels Correlate with Response to Pirfenidone in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 191, Article No. A4398.
[45] Bergantini, L., Bargagli, E., Cameli, P., Cekorja, B., Lanzarone, N., Pianigiani, L., et al. (2019) Serial KL-6 Analysis in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Respiratory Investigation, 57, 290-291. [Google Scholar] [CrossRef] [PubMed]

为你推荐